UroGen Pharma Overview
UroGen Pharma (URGN) has a ROE of 107.22%, above the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow107.22%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for URGN is 107.22%. That is above the Healthcare sector average of 29.33%. Investors often review this figure alongside UroGen Pharma's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, URGN currently prints 107.22% for ROE, while the sector average sits near 29.33%. That is roughly 265.6% above the sector mean. Large gaps often invite a closer look at UroGen Pharma's growth, margins, and balance sheet.
Return on Equity shows how effectively UroGen Pharma converts resources into returns. At 107.22%, URGN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting URGN's ROE (107.22%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack UroGen Pharma's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
